Skip to main content

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Project description

Researchers ignore capitalism when it comes to three of the most threatening infectious diseases

The 2014-2016 Ebola crisis in West Africa sounded an alarm about the major shortcomings in global preparedness for serious epidemics and public health emergencies. The second annual World Health Organisation Blueprint list of 2018 identified eight diseases and pathogens with serious epidemic potential that lacked efficacious drugs and/or vaccines. Ebola virus disease (EVD) and Rift Valley fever (RVF) are among them. Chikungunya (CHIKV) was considered for inclusion and deemed a major health risk. These diseases favour low- and middle-income countries and market incentives for vaccine development are lacking. EU funding of the ECRC project is helping the Coalition for Epidemic Preparedness Innovation in Norway accelerate vaccine development to protect the health and economic well-being of millions.

Call for proposal

H2020-FPA-SGA-SC1-CEPI-2019

See other projects for this call

Sub call

H2020-SGA-SC1-CEPI-2019

Coordinator

COALITION FOR EPIDEMIC PREPAREDNESS INNOVATION
Net EU contribution
€ 36 000 000,00
Address
Marcus Thranses Gate 2
0473 Oslo
Norway

See on map

Region
Norge Oslo og Viken Oslo
Activity type
Research Organisations
Non-EU contribution
€ 15 428 572,00